Humoral innate immune response and disease

Clinical Immunology

Volumn 144, Issue 2, 2012, Pages 142-158

  Shishido, Stephanie N ^a   Varahan, Sriram ^a   Yuan, Kai ^a   Li, Xiangdong ^a   Fleming, Sherry D ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Cancer; Complement; Contact cascade; Infection; Natural antibodies; Pentraxins

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; PENTRAXIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; BORRELIA; CARDIOVASCULAR RISK; CHRONIC DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DISEASE COURSE; ENTEROCOCCUS FAECALIS; ESCHERICHIA; HAEMOPHILUS INFLUENZAE; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; INFECTION CONTROL; INNATE IMMUNITY; NEISSERIA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS INFECTION;

ANIMALS; ATHEROSCLEROSIS; CHRONIC DISEASE; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; INFECTION; NEOPLASMS;

EID: 84863448624     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.06.002     Document Type: Review

References (214)

1. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 2004, 5:981-986.
2. Kimura Y., Madhavan M., Call M.K., Santiago W., Tsonis P.A., Lambris J.D., Del Rio-Tsonis K. Expression of complement 3 and complement 5 in newt limb and lens regeneration. J. Immunol. 2003, 170:2331-2339.
3. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3357-3361.
4. Renne T. The procoagulant and proinflammatory plasma contact system. Semin. Immunopathol. 2012, 34:31-41.
5. Imamura T., Tanase S., Szmyd G., Kozik A., Travis J., Potempa J. Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases from Staphylococcus aureus. J. Exp. Med. 2005, 201:1669-1676.
6. Hamad O.A., Back J., Nilsson P.H., Nilsson B., Ekdahl K.N. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv. Exp. Med. Biol. 2012, 946:185-205.
7. Amara U., Rittirsch D., Flierl M., Bruckner U., Klos A., Gebhard F., Lambris J.D., Huber-Lang M. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 2008, 632:71-79.
8. Avrameas S. Natural autoantibodies - from horror autotoxicus to gnothi seauton. Immunol. Today 1991, 12:154-159.
9. Binder C.J., Shaw P.X., Chang M.K., Boullier A., Hartvigsen K., Horkko S., Miller Y.I., Woelkers D.A., Corr M., Witztum J.L. The role of natural antibodies in atherogenesis. J. Lipid Res. 2005, 46:1353-1363.
10. Ochsenbein A.F., Fehr T., Lutz C., Suter M., Brombacher F., Hengartner H., Zinkernagel R.M. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999, 286:2156-2159.
11. Du Clos T.W., Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res. 2004, 30:261-277.
12. Bassi N., Zampieri S., Ghirardello A., Tonon M., Zen M., Cozzi F., Doria A. Pentraxins, anti-pentraxin antibodies, and atherosclerosis. Clin. Rev. Allergy Immunol. 2009, 37:36-43.
13. Pepys M.B., Baltz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 1983, 34:141-212.
14. Hirschfield G.M., Herbert J., Kahan M.C., Pepys M.B. Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. J. Immunol. 2003, 171:6046-6051.
15. Moalli F., Doni A., Deban L., Zelante T., Zagarella S., Bottazzi B., Romani L., Mantovani A., Garlanda C. Role of complement and Fc{gamma} receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood 2010, 116:5170-5180.
16. Mold C., Baca R., Du Clos T.W. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J. Autoimmun. 2002, 19:147-154.
17. Mold C., Gresham H.D., Du Clos T.W. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J. Immunol. 2001, 166:1200-1205.
18. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20:34-50.
19. Qu H., Ricklin D., Lambris J.D. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 2009, 47:185-195.
20. Wallis R. Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway. Immunobiology 2007, 212:289-299.
21. Sorensen R., Thiel S., Jensenius J.C. Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin. Immunopathol. 2005, 27:299-319.
22. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6:132-142.
23. Laarman A., Milder F., van Strijp J., Rooijakkers S. Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications. J. Mol. Med. (Berl.) 2010, 88:115-120.
24. Janulczyk R., Iannelli F., Sjoholm A.G., Pozzi G., Bjorck L. Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J. Biol. Chem. 2000, 275:37257-37263.
25. Jarva H., Jokiranta T.S., Wurzner R., Meri S. Complement resistance mechanisms of streptococci. Mol. Immunol. 2003, 40:95-107.
26. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., Ngampasutadol J., Vogel U., Granoff D.M., Ram S. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 2006, 177:501-510.
27. Kraiczy P., Skerka C., Kirschfink M., Brade V., Zipfel P.F. Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H. Eur. J. Immunol. 2001, 31:1674-1684.
28. Ren B., McCrory M.A., Pass C., Bullard D.C., Ballantyne C.M., Xu Y.Y., Briles D.E., Szalai A.J. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J. Immunol. 2004, 173:7506-7512.
29. Hammel M., Sfyroera G., Ricklin D., Magotti P., Lambris J.D., Geisbrecht B.V. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 2007, 8:430-437.
30. Lee L.Y.L., Hook M., Haviland D., Wetsel R.A., Yonter E.O., Syribeys P., Vernachio J., Brown E.L. Inhibition of complement activation by a secreted Staphylococcus aureus protein. J. Infect. Dis. 2004, 190:571-579.
31. Akesson P., Sjoholm A.G., Bjorck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J. Biol. Chem. 1996, 271:1081-1088.
32. Thurlow L.R., Thomas V.C., Narayanan S., Olson S., Fleming S.D., Hancock L.E. Gelatinase contributes to the pathogenesis of endocarditis caused by Enterococcus faecalis. Infect. Immun. 2010, 78:4936-4943.
33. Kalter E.S., Daha M.R., Tencate J.W., Verhoef J., Bouma B.N. Activation and inhibition of hageman factor-dependent pathways and the complement-system in uncomplicated bacteremia or bacterial shock. J. Infect. Dis. 1985, 151:1019-1027.
34. Frick I.M., Bjorck L., Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb. Haemost. 2007, 98:497-502.
35. Lottenberg R. Contact activation proteins and the bacterial surface. Trends Microbiol. 1996, 4:413-414. (discussion 414-415).
36. Ben Nasr A., Olsen A., Sjobring U., Muller-Esterl W., Bjorck L. Assembly of human contact phase proteins and release of bradykinin at the surface of curli-expressing Escherichia coli. Mol. Microbiol. 1996, 20:927-935.
37. Herwald H., Morgelin M., Bjorck L. Contact activation by pathogenic bacteria: a virulence mechanism contributing to the pathophysiology of sepsis. Scand. J. Infect. Dis. 2003, 35:604-607.
38. Kalter E.S., van Dijk W.C., Timmerman A., Verhoef J., Bouma B.N. Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J. Infect. Dis. 1983, 148:682-691.
39. Scott C.F., Whitaker E.J., Hammond B.F., Colman R.W. Purification and characterization of a potent 70-Kda thiol lysylproteinase (Lys-Gingivain) from porphyromonas-gingivalis that cleaves kininogens and fibrinogen. J. Biol. Chem. 1993, 268:7935-7942.
40. Herwald H., Collin M., Muller-Esterl W., Bjorck L. Streptococcal cysteine proteinase releases kinins: a virulence mechanism. J. Exp. Med. 1996, 184:665-673.
41. Molla A., Yamamoto T., Akaike T., Miyoshi S., Maeda H. Activation of hageman-factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem. 1989, 264:10589-10594.
42. Mattsson E., Herwald H., Cramer H., Persson K., Sjobring U., Bjorck L. Staphylococcus aureus induces release of bradykinin in human plasma. Infect. Immun. 2001, 69:3877-3882.
43. Leeb-Lundberg L.M., Marceau F., Muller-Esterl W., Pettibone D.J., Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 2005, 57:27-77.
44. Quan C., Berneman A., Pires R., Avrameas S., Bouvet J.P. Salivary natural antibodies as a basic immune barrier against group A streptococci. Streptococci Host 1997, 418:881-885.
45. Petras G., Nemeth C. Natural antibodies in Pseudomonas aeruginosa infections. Acta Microbiol. Acad. Sci. Hung. 1979, 26:265-272.
46. Cohen I.R. Natural and immune human antibodies reactive with antigens of virulent Neisseria gonorrhoeae - immunoglobulins G M and A. J. Bacteriol. 1967, 94:141-148.
47. Michael J.G., Whitby J.L., Landy M. Studies on natural antibodies to gram-negative bacteria. J. Exp. Med. 1962, 115:131-146.
48. Briles D.E., Nahm M., Schroer K., Davie J., Baker P., Kearney J., Barletta R. Anti-phosphocholine antibodies found in normal mouse serum are protective against intravenous infection with Type-3 Streptococcus-pneumoniae. J. Exp. Med. 1981, 153:694-705.
49. Backhausz R., Meretey K., Petras G. Changes in the natural antibody titer in course of the infectious complications developing in patients given artificial respiration. Ann. Immunol. Hung. 1972, 16:51-63.
50. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis. 2004, 39:206-217.
51. Doni A., Peri G., Chieppa M., Allavena P., Pasqualini F., Vago L., Romani L., Garlanda C., Mantovani A. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur. J. Immunol. 2003, 33:2886-2893.
52. Vouret-Craviari V., Matteucci C., Peri G., Poli G., Introna M., Mantovani A. Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Infect. Immun. 1997, 65:1345-1350.
53. Polentarutti N., Bottazzi B., Di Santo E., Blasi E., Agnello D., Ghezzi P., Introna M., Bartfai T., Richards G., Mantovani A. Inducible expression of the long pentraxin PTX3 in the central nervous system. J. Neuroimmunol. 2000, 106:87-94.
54. Casey R., Newcombe J., McFadden J., Bodman-Smith K.B. The acute-phase reactant C-reactive protein binds to phosphorylcholine-expressing Neisseria meningitidis and increases uptake by human phagocytes. Infect. Immun. 2008, 76:1298-1304.
55. Sjoberg A.P., Trouw L.A., Blom A.M. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009, 30:83-90.
56. Bottazzi B., Doni A., Garlanda C., Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010, 28:157-183.
57. Alexandre K.B., Gray E.S., Lambson B.E., Moore P.L., Choge I.A., Mlisana K., Karim S.S., McMahon J., O'Keefe B., Chikwamba R., Morris L. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins. Griffithsin, Cyanovirin-N and Scytovirin, Virology 2010, 402:187-196.
58. Ip W.K., Chan K.H., Law H.K., Tso G.H., Kong E.K., Wong W.H., To Y.F., Yung R.W., Chow E.Y., Au K.L., Chan E.Y., Lim W., Jensenius J.C., Turner M.W., Peiris J.S., Lau Y.L. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J. Infect. Dis. 2005, 191:1697-1704.
59. Ji X., Olinger G.G., Aris S., Chen Y., Gewurz H., Spear G.T. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J. Gen. Virol. 2005, 86:2535-2542.
60. Gonzalez S.F., Lukacs-Kornek V., Kuligowski M.P., Pitcher L.A., Degn S.E., Turley S.J., Carroll M.C. Complement-dependent transport of antigen into B cell follicles. J. Immunol. 2010, 185:2659-2664.
61. Fang Y., Xu C., Fu Y.X., Holers V.M., Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 1998, 160:5273-5279.
62. Bradbury L.E., Kansas G.S., Levy S., Evans R.L., Tedder T.F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 1992, 149:2841-2850.
63. Mehlhop E., Whitby K., Oliphant T., Marri A., Engle M., Diamond M.S. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J. Virol. 2005, 79:7466-7477.
64. Bonaparte R.S., Hair P.S., Banthia D., Marshall D.M., Cunnion K.M., Krishna N.K. Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway. J. Virol. 2008, 82:817-827.
65. Zhang J., Li G., Liu X., Wang Z., Liu W., Ye X. Influenza A virus M1 blocks the classical complement pathway through interacting with C1qA. J. Gen. Virol. 2009, 90:2751-2758.
66. Avirutnan P., Fuchs A., Hauhart R.E., Somnuke P., Youn S., Diamond M.S., Atkinson J.P. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J. Exp. Med. 2010, 207:793-806.
67. Lubinski J., Nagashunmugam T., Friedman H.M. Viral interference with antibody and complement. Semin. Cell Dev. Biol. 1998, 9:329-337.
68. Kostavasili I., Sahu A., Friedman H.M., Eisenberg R.J., Cohen G.H., Lambris J.D. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J. Immunol. 1997, 158:1763-1771.
69. Kapadia S.B., Molina H., van Berkel V., Speck S.H., Virgin H.W.t. Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. J. Virol. 1999, 73:7658-7670.
70. Albrecht J.C., Fleckenstein B. New member of the multigene family of complement control proteins in herpesvirus saimiri. J. Virol. 1992, 66:3937-3940.
71. Mullick J., Bernet J., Singh A.K., Lambris J.D., Sahu A. Kaposi's sarcoma associated herpesvirus (human herpesvirus 8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J. Virol. 2003, 77:3878-3881.
72. Spiller O.B., Robinson M., O'Donnell E., Milligan S., Morgan B.P., Davison A.J., Blackbourn D.J. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J. Virol. 2003, 77:592-599.
73. Virgin H.W.t., Latreille P., Wamsley P., Hallsworth K., Weck K.E., Dal Canto A.J., Speck S.H. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 1997, 71:5894-5904.
74. Liszewski M.K., Leung M.K., Hauhart R., Buller R.M., Bertram P., Wang X., Rosengard A.M., Kotwal G.J., Atkinson J.P. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J. Immunol. 2006, 176:3725-3734.
75. Moulton E.A., Bertram P., Chen N., Buller R.M., Atkinson J.P. Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement. J. Virol. 2010, 84:9128-9139.
76. Rosengard A.M., Liu Y., Nie Z., Jimenez R. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8808-8813.
77. Sahu A., Isaacs S.N., Soulika A.M., Lambris J.D. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. 1998, 160:5596-5604.
78. Saifuddin M., Parker C.J., Peeples M.E., Gorny M.K., Zolla-Pazner S., Ghassemi M., Rooney I.A., Atkinson J.P., Spear G.T. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 1995, 182:501-509.
79. Spear G.T., Lurain N.S., Parker C.J., Ghassemi M., Payne G.H., Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J. Immunol. 1995, 155:4376-4381.
80. Datta P.K., Rappaport J. HIV and complement: hijacking an immune defense. Biomed. Pharmacother. 2006, 60:561-568.
81. Popovic M., Paskas S., Zivkovic M., Burysek L., Laumonnier Y. Human cytomegalovirus increases HUVEC sensitivity to thrombin and modulates expression of thrombin receptors. J. Thromb. Thrombolysis 2010, 30:164-171.
82. Laine O., Makela S., Mustonen J., Huhtala H., Szanto T., Vaheri A., Lassila R., Joutsi-Korhonen L. Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. Thromb. Res. 2010, 126:154-158.
83. Etingin O.R., Silverstein R.L., Friedman H.M., Hajjar D.P. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell 1990, 61:657-662.
84. Kaner R.J., Iozzo R.V., Ziaie Z., Kefalides N.A. Inhibition of proteoglycan synthesis in human endothelial cells after infection with herpes simplex virus type 1 in vitro. Am. J. Respir. Cell Mol. Biol. 1990, 2:423-431.
85. Hsue P.Y., Scherzer R., Grunfeld C., Nordstrom S.M., Schnell A., Kohl L.P., Nitta E., Martin J.N., Deeks S.G., Weiss E.J. HIV Infection Is Associated With Decreased Thrombin Generation. Clin. Infect. Dis. 2012, 54:1196-1203.
86. Lin S.W., Chuang Y.C., Lin Y.S., Lei H.Y., Liu H.S., Yeh T.M. Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation prothrombin/thrombin and inhibits prothrombin activation. J. Infect. 2012, 325-334.
87. Butthep P., Bunyaratvej A., Bhamarapravati N. Dengue virus and endothelial cell: a related phenomenon to thrombocytopenia and granulocytopenia in dengue hemorrhagic fever. Southeast Asian J. Trop. Med. Public Health 1993, 24(Suppl. 1):246-249.
88. Van Dam-Mieras M.C., Muller A.D., van Hinsbergh V.W., Mullers W.J., Bomans P.H., Bruggeman C.A. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb. Haemost. 1992, 68:364-370.
89. Lenman A., Muller S., Nygren M.I., Frangsmyr L., Stehle T., Arnberg N. Coagulation factor IX mediates serotype-specific binding of species A adenoviruses to host cells. J. Virol. 2011, 85:13420-13431.
90. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 1992, 44:1-80.
91. Battegay M., Cooper S., Althage A., Banziger J., Hengartner H., Zinkernagel R.M. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods 1991, 33:191-198.
92. Baumgarth N., Chen J., Herman O.C., Jager G.C., Herzenberg L.A. The role of B-1 and B-2 cells in immune protection from influenza virus infection. Curr. Top. Microbiol. Immunol. 2000, 252:163-169.
93. Clarke S.H., Huppi K., Ruezinsky D., Staudt L., Gerhard W., Weigert M. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 1985, 161:687-704.
94. Baccala R., Quang T.V., Gilbert M., Ternynck T., Avrameas S. Two murine natural polyreactive autoantibodies are encoded by nonmutated germ-line genes. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:4624-4628.
95. Baumgarth N., Herman O.C., Jager G.C., Brown L.E., Herzenberg L.A., Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 2000, 192:271-280.
96. Thornton B.P., Vetvicka V., Ross G.D. Natural antibody and complement-mediated antigen-processing and presentation by B-lymphocytes. J. Immunol. 1994, 152:1727-1737.
97. Mairuhu A.T., Peri G., Setiati T.E., Hack C.E., Koraka P., Soemantri A., Osterhaus A.D., Brandjes D.P., van der Meer J.W., Mantovani A., van Gorp E.C. Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J. Med. Virol. 2005, 76:547-552.
98. Bozza S., Bistoni F., Gaziano R., Pitzurra L., Zelante T., Bonifazi P., Perruccio K., Bellocchio S., Neri M., Iorio A.M., Salvatori G., De Santis R., Calvitti M., Doni A., Garlanda C., Mantovani A., Romani L. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 2006, 108:3387-3396.
99. Reading P.C., Bozza S., Gilbertson B., Tate M., Moretti S., Job E.R., Crouch E.C., Brooks A.G., Brown L.E., Bottazzi B., Romani L., Mantovani A. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J. Immunol. 2008, 180:3391-3398.
100. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1214-1219.
101. Niculescu F., Rus H. Complement activation and atherosclerosis. Mol. Immunol. 1999, 36:949-955.
102. Recinos A., Carr B.K., Bartos D.B., Boldogh I., Carmical J.R., Belalcazar L.M., Brasier A.R. Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. Physiol. Genomics 2004, 19:131-142.
103. Malik T.H., Cortini A., Carassiti D., Boyle J.J., Haskard D.O., Botto M. The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2010, 122:1948-1956.
104. Schmiedt W., Kinscherf R., Deigner H.P., Kamencic H., Nauen O., Kilo J., Oelert H., Metz J., Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1790-1795.
105. Vlaicu R., Niculescu F., Rus H.G., Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985, 57:163-177.
106. Wu G., Hu W., Shahsafaei A., Song W., Dobarro M., Sukhova G.K., Bronson R.R., Shi G.P., Rother R.P., Halperin J.A., Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res. 2009, 104:550-558.
107. Lewis R.D., Jackson C.L., Morgan B.P., Hughes T.R. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Mol. Immunol. 2010, 47:1098-1105.
108. Yun S., Leung V.W., Botto M., Boyle J.J., Haskard D.O. Brief report: accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59. Arterioscler. Thromb. Va c. Biol. 2008, 28:1714-1716.
109. Hartvigsen K., Chou M.Y., Hansen L.F., Shaw P.X., Tsimikas S., Binder C.J., Witztum J.L. The role of innate immunity in atherogenesis. J. Lipid Res. 2009, 50:S388-S393. (Suppl.).
110. Chang M.K., Binder C.J., Miller Y.I., Subbanagounder G., Silverman G.J., Berliner J.A., Witztum J.L. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 2004, 200:1359-1370.
111. Horkko S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., Friedman P., Dennis E.A., Curtiss L.K., Palinski W., Witztum J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 1999, 103:117-128.
112. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., Shaw P.X., Palinski W., Witztum J.L., Silverman G.J. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 2003, 9:736-743.
113. Haas M.S., Alicot E.M., Schuerpf F., Chiu I., Li J., Moore F.D., Carroll M.C. Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc. Res. 2010, 87:618-627.
114. Zhang M., Michael L.H., Grosjean S.A., Kelly R.A., Carroll M.C., Entman M.L. The role of natural IgM in myocardial ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2006, 62-67.
115. Miller G.J., Esnouf M.P., Burgess A.I., Cooper J.A., Mitchell J.P. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2103-2106.
116. Merlo C., Wuillemin W.A., Redondo M., Furlan M., Sulzer I., Kremer-Hovinga J., Binder B.R., Lammle B. Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis 2002, 161:261-267.
117. Gailani D., Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2507-2513.
118. Manolov D.E., Koenig W., Hombach V., Torzewski J. C-reactive protein and atherosclerosis. Is there a causal link?. Histol. Histopathol. 2003, 18:1189-1193.
119. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., Dhillon B., Weisel R.D., Li R.K., Mickle D.A., Stewart D.J. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
120. Devaraj S., Xu D.Y., Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404.
121. Verma S., Yeh E.T. C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R1253-R1256. (discussion R1257-1258).
122. Ryu J., Lee C.W., Shin J.A., Park C.S., Kim J.J., Park S.J., Han K.H. FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc. Res. 2007, 75:555-565.
123. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2348-2354.
124. Chang M.K., Binder C.J., Torzewski M., Witztum J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13043-13048.
125. Abd T.T., Eapen D.J., Bajpai A., Goyal A., Dollar A., Sperling L. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr. Atheroscler. Rep. 2011, 13:154-161.
126. Mold C., Gewurz H., Du Clos T.W. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999, 42:23-30.
127. Distelmaier K., Adlbrecht C., Jakowitsch J., Winkler S., Dunkler D., Gerner C., Wagner O., Lang I.M., Kubicek M. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb. Haemost. 2009, 102:564-572.
128. Mihlan M., Blom A.M., Kupreishvili K., Lauer N., Stelzner K., Bergstrom F., Niessen H.W., Zipfel P.F. Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J. 2011, 25:4198-4210.
129. Rocken C., Tautenhahn J., Buhling F., Sachwitz D., Vockler S., Goette A., Burger T. Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler. Thromb. Vasc. Biol. 2006, 26:676-677.
130. Myers S.L., Jones S., Jahn T.R., Morten I.J., Tennent G.A., Hewitt E.W., Radford S.E. A systematic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neutral pH. Biochemistry 2006, 45:2311-2321.
131. Stewart C.R., Tseng A.A., Mok Y.F., Staples M.K., Schiesser C.H., Lawrence L.J., Varghese J.N., Moore K.J., Howlett G.J. Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. Biochemistry 2005, 44:9108-9116.
132. Savchenko A., Imamura M., Ohashi R., Jiang S., Kawasaki T., Hasegawa G., Emura I., Iwanari H., Sagara M., Tanaka T., Hamakubo T., Kodama T., Naito M. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J. Pathol. 2008, 215:48-55.
133. Peri G., Introna M., Corradi D., Iacuitti G., Signorini S., Avanzini F., Pizzetti F., Maggioni A.P., Moccetti T., Metra M., Cas L.D., Ghezzi P., Sipe J.D., Re G., Olivetti G., Mantovani A., Latini R. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
134. Napoleone E., Di Santo A., Bastone A., Peri G., Mantovani A., de Gaetano G., Donati M.B., Lorenzet R. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler. Thromb. Vasc. Biol. 2002, 22:782-787.
135. de Visser K.E., Korets L.V., Coussens L.M. Early neoplastic progression is complement independent. Neoplasia 2004, 6:768-776.
136. Ostrand-Rosenberg S. Cancer and complement. Nat. Biotechnol. 2008, 26:1348-1349.
137. Gelderman K.A., Tomlinson S., Ross G.D., Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004, 25:158-164.
138. Xia Y., Vetvicka V., Yan J., Hanikyrova M., Mayadas T., Ross G.D. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 1999, 162:2281-2290.
139. Niculescu F., Badea T., Rus H. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 1999, 142:47-56.
140. Yamakawa M., Yamada K., Tsuge T., Ohrui H., Ogata T., Dobashi M., Imai Y. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994, 73:2808-2817.
141. Bjorge L., Hakulinen J., Vintermyr O.K., Jarva H., Jensen T.S., Iversen O.E., Meri S. Ascitic complement system in ovarian cancer. Br. J. Cancer 2005, 92:895-905.
142. Fishelson Z., Donin N., Zell S., Schultz S., Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 2003, 40:109-123.
143. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. 1999, 36:929-939.
144. Donin N., Jurianz K., Ziporen L., Schultz S., Kirschfink M., Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol. 2003, 131:254-263.
145. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9:1225-1235.
146. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
147. Haura E.B., Turkson J., Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2005, 2:315-324.
148. Schraufstatter I.U., Trieu K., Sikora L., Sriramarao P., DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J. Immunol. 2002, 169:2102-2110.
149. Venkatesha R.T., Berla Thangam E., Zaidi A.K., Ali H. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol. Immunol. 2005, 42:581-587.
150. Fosbrink M., Niculescu F., Rus H. The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol. Res. 2005, 31:37-46.
151. Peng H., Takano T., Papillon J., Bijian K., Khadir A., Cybulsky A.V. Complement activates the c-Jun N-terminal kinase/stress-activated protein kinase in glomerular epithelial cells. J. Immunol. 2002, 169:2594-2601.
152. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838-3846.
153. Li Q., Pan P.Y., Gu P., Xu D., Chen S.H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. 2004, 64:1130-1139.
154. Bronte V., Serafini P., Apolloni E., Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 2001, 24:431-446.
155. Young M.R., Wright M.A., Matthews J.P., Malik I., Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J. Immunol. 1996, 156:1916-1922.
156. Livingston P.O., Wong G.Y., Adluri S., Tao Y., Padavan M., Parente R., Hanlon C., Calves M.J., Helling F., Ritter G., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 1994, 12:1036-1044.
157. Martin S.E., Martin W.J. Anti-tumor antibodies in normal mouse sera. Int. J. Cancer 1975, 15:658-664.
158. Schwartz-Albiez R., Laban S., Eichmuller S., Kirschfink M. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? Autoimmun. Rev. 2008, 7:491-495.
159. Anderson K.S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J. Proteome Res. 2005, 4:1123-1133.
160. Springer G.F. T and Tn, general carcinoma autoantigens. Science 1984, 224:1198-1206.
161. Springer G.F., Desai P.R., Scanlon E.F. Blood group MN precursors as human breast carcinoma-associated antigens and "naturally" occurring human cytotoxins against them. Cancer 1976, 37:169-176.
162. Cao Y., Merling A., Karsten U., Goletz S., Punzel M., Kraft R., Butschak G., Schwartz-Albiez R. Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int. J. Cancer 2008, 123:89-99.
163. Cao W., Bao C., Padalko E., Lowenstein C.J. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J. Exp. Med. 2008, 205:1491-1503.
164. Brandlein S., Beyer I., Eck M., Bernhardt W., Hensel F., Muller-Hermelink H.K., Vollmers H.P. Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res. 2003, 63:2052-2061.
165. Brandlein S., Eck M., Strobel P., Wozniak E., Muller-Hermelink H.K., Hensel F., Vollmers H.P. PAM-1, a natural human IgM antibody as new tool for detection of breast and prostate precursors. Hum. Antibodies 2004, 13:97-104.
166. Brandlein S., Pohle T., Ruoff N., Wozniak E., Muller-Hermelink H.K., Vollmers H.P. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 2003, 63:7995-8005.
167. Vollmers H.P., Brandlein S. The "early birds": natural IgM antibodies and immune surveillance. Histol. Histopathol. 2005, 20:927-937.
168. Vollmers H.P., Brandlein S. Death by stress: natural IgM-induced apoptosis. Methods Find. Exp. Clin. Pharmacol. 2005, 27:185-191.
169. Dummer R., Mittelman A., Fanizzi F.P., Lucchese G., Willers J., Kanduc D. Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int. J. Cancer 2004, 111:720-726.
170. Brichory F., Beer D., Le Naour F., Giordano T., Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001, 61:7908-7912.
171. Conroy S.E., Gibson S.L., Brunstrom G., Isenberg D., Luqmani Y., Latchman D.S. Autoantibodies to 90kD heat-shock protein in sera of breast cancer patients. Lancet 1995, 345:126.
172. Vlock D.R., Scalise D., Schwartz D.R., Richter D.E., Krause C.J., Baker S.R., Carey T.E. Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration. Cancer Res. 1989, 49:1361-1365.
173. Taylor D.D., Homesley H.D., Doellgast G.J. Identification of antigenic components recognized by "membrane-bound" antibodies from ovarian cancer patients. Am. J. Reprod. Immunol. 1984, 6:179-184.
174. Vogl F.D., Frey M., Kreienberg R., Runnebaum I.B. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br. J. Cancer 2000, 83:1338-1343.
175. Pohle T., Brandlein S., Ruoff N., Muller-Hermelink H.K., Vollmers H.P. Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 2004, 64:3900-3906.
176. Brandlein S., Rauschert N., Rasche L., Dreykluft A., Hensel F., Conzelmann E., Muller-Hermelink H.K., Vollmers H.P. The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. Mol. Cancer Ther. 2007, 6:326-333.
177. Taylor D.D., Gercel-Taylor C., Parker L.P. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol. Oncol. 2009, 115:112-120.
178. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 1985, 44:139-266.
179. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64:327-336.
180. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb. Haemost. 1999, 82:298-304.
181. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72:1-22.
182. Duffy M.J. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem. Soc. Trans. 2002, 30:207-210.
183. Duffy M.J., O'Grady P., Devaney D., O'Siorain L., Fennelly J.J., Lijnen H.J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988, 62:531-533.
184. Oka T., Ishida T., Nishino T., Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res. 1991, 51:3522-3525.
185. Pedersen H., Grondahl-Hansen J., Francis D., Osterlind K., Hansen H.H., Dano K., Brunner N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 1994, 54:120-123.
186. Hasui Y., Marutsuka K., Suzumiya J., Kitada S., Osada Y., Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int. J. Cancer 1992, 50:871-873.
187. Heiss M.M., Allgayer H., Gruetzner K.U., Funke I., Babic R., Jauch K.W., Schildberg F.W. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat. Med. 1995, 1:1035-1039.
188. Nekarda H., Schmitt M., Ulm K., Wenninger A., Vogelsang H., Becker K., Roder J.D., Fink U., Siewert J.R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994, 54:2900-2907.
189. Mulcahy H.E., Duffy M.J., Gibbons D., McCarthy P., Parfrey N.A., O'Donoghue D.P., Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994, 344:583-584.
190. Duffy M.J. Plasminogen activators and cancer. Blood Coagul. Fibrinolysis 1990, 1:681-687.
191. Crowley C.W., Cohen R.L., Lucas B.K., Liu G., Shuman M.A., Levinson A.D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5021-5025.
192. Kook Y.H., Adamski J., Zelent A., Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 1994, 13:3983-3991.
193. Saito A., Pietromonaco S., Loo A.K., Farquhar M.G. Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9725-9729.
194. Odekon L.E., Blasi F., Rifkin D.B. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J. Cell. Physiol. 1994, 158:398-407.
195. Werb Z., Tremble P., Damsky C.H. Regulation of extracellular matrix degradation by cell-extracellular matrix interactions. Cell Differ. Dev. 1990, 32:299-306.
196. Van Roy F., Mareel M. Tumour invasion: effects of cell adhesion and motility. Trends Cell Biol. 1992, 2:163-169.
197. Frixen U.H., Nagamine Y. Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherin-dependent cell-cell adhesion. Cancer Res. 1993, 53:3618-3623.
198. Matsumura Y., Maruo K., Kimura M., Yamamoto T., Konno T., Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 1991, 82:732-741.
199. Maeda H., Matsumura Y., Kato H. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 1988, 263:16051-16054.
200. Maeda H., Wu J., Okamoto T., Maruo K., Akaike T. Kallikrein-kinin in infection and cancer. Immunopharmacology 1999, 43:115-128.
201. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
202. Matsumura Y., Kimura M., Yamamoto T., Maeda H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 1988, 79:1327-1334.
203. Hurlimann J., Thorbecke G.J., Hochwald G.M. The liver as the site of C-reactive protein formation. J. Exp. Med. 1966, 123:365-378.
204. Ganapathi M.K., Rzewnicki D., Samols D., Jiang S.L., Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J. Immunol. 1991, 147:1261-1265.
205. Lee J.G., Cho B.C., Bae M.K., Lee C.Y., Park I.K., Kim D.J., Ahn S.V., Chung K.Y. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 2009, 63:106-110.
206. Chiu H.M., Lin J.T., Chen T.H., Lee Y.C., Chiu Y.H., Liang J.T., Shun C.T., Wu M.S. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am. J. Gastroenterol. 2008, 103:2317-2325.
207. Groblewska M., Mroczko B., Wereszczynska-Siemiatkowska U., Kedra B., Lukaszewicz M., Baniukiewicz A., Szmitkowski M. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin. Chem. Lab. Med. 2008, 46:1423-1428.
208. Coombes R.C., Powles T.J., Gazet J.C., Ford H.T., Sloane J.P., Laurence D.J., Neville A.M. Biochemical markers in human breast cancer. Lancet 1977, 1:132-134.
209. Duffy S.A., Taylor J.M., Terrell J.E., Islam M., Li Y., Fowler K.E., Wolf G.T., Teknos T.N. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008, 113:750-757.
210. Liao W.C., Lin J.T., Wu C.Y., Huang S.P., Lin M.T., Wu A.S., Huang Y.J., Wu M.S. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin. Cancer Res. 2008, 14:428-434.
211. Macri A., Versaci A., Loddo S., Scuderi G., Travagliante M., Trimarchi G., Teti D., Famulari C. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 2006, 11:184-193.
212. Willeke F., Assad A., Findeisen P., Schromm E., Grobholz R., von Gerstenbergk B., Mantovani A., Peri S., Friess H.H., Post S., von Knebel Doeberitz M., Schwarzbach M.H. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur. J. Cancer 2006, 42:2639-2646.
213. Diamandis E.P., Goodglick L., Planque C., Thornquist M.D. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin. Cancer Res. 2011, 17:2395-2399.
214. Margheri F., Serrati S., Lapucci A., Anastasia C., Giusti B., Pucci M., Torre E., Bianchini F., Calorini L., Albini A., Ventura A., Fibbi G., Del Rosso M. Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice. Neoplasia 2009, 11:1106-1115.